Showing results (1281-1290 of 1,306) with videos related to

Sort By:
Pageof 131
Cell Chemical Biology|March 4, 2021
A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell deathDuncan E Scott, Nicola J Francis-Newton, May E Marsh, et al.
Journal of Cancer|September 11, 2020
The development of bronchoscopy in China: a national cross-sectional studyDongchen Shi, Fuqi Li, Kaicheng Wang, et al.
JAMA Ophthalmology|June 8, 2018
Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical TrialDavid G Birch, Paul S Bernstein, Alessandro Iannacone, et al.
BMJ Open|August 4, 2023
[18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trialEng-Siew Koh, Hui K Gan, Clare Senko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancerAslı D Munzur, Cameron Herberts, Edmond M Kwan, et al.
Physics and Imaging in Radiation Oncology|April 8, 2024
[18]F-fluoroethyl-l-tyrosine positron emission tomography for radiotherapy target delineation: Results from a Radiation Oncology credentialing programNathaniel Barry, Eng-Siew Koh, Martin A Ebert, et al.
US CLIVAR Reports|October 22, 2019
ARCTIC CHANGE AND POSSIBLE INFLUENCE ON MID-LATITUDE CLIMATE AND WEATHER: A US CLIVAR White PaperJ Cohen, X Zhang, J Francis, et al.
European Urology|April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901)Louise Emmett, Nathan Papa, Oliver Sartor, et al.
European Heart Journal|May 24, 2026
Endurance exercise remodels pulmonary vein sleeve myocytes and promotes a proarrhythmic atrial substrateLuca Soattin, Leila Topal, Roman Tikhomirov, et al.
European Urology Oncology|December 7, 2023
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate CancerJames P Buteau, Daniel Moon, Michael T Fahey, et al.
Pageof 131